Alvocidib Hydrochloride

Phase 2Small molecule

NNational Cancer Institute (NCI)

Alvocidib Hydrochloride is one of 106 small molecule programs targeting B-cell neoplasm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell NeoplasmActive, not recruiting

Germ Cell TumorActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

B-Cell NeoplasmPhase 1

Active, not recruiting

Germ Cell TumorPhase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

367 competitors in Chronic Lymphocytic Leukemia

#DrugCompanyPhaseTrials

Gazyva

Roche

Phase 3

58 2

Rituxan

Venclexta

50 4

Calquence

AstraZeneca

Phase 3

23 5

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

42 6

Nipent

Pfizer

Phase 3

13 7

Brukinsa

BBeOne Medicines

Phase 3

15 8

Medrol

Pfizer

Phase 3

1 9

Adcetris

Pfizer

Phase 3

1 10

Beqalzi

BBeOne Medicines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia2 trials

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01076556·9 enrolled

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00735930·39 enrolled

Relapsed or Refractory1 trial

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT04493099

Germ Cell Tumor1 trial

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00957905·36 enrolled

B-cell neoplasm1 trial

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00082784·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Alvocidib Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alvocidib Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alvocidib Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Alvocidib Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Lymphocytic Leukemia2 trials

Relapsed or Refractory1 trial

Germ Cell Tumor1 trial

B-cell neoplasm1 trial

References

Drug Info

Quick Facts

Related News